After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
As a NASDAQ listed company, BGNE falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of BeiGene Ltd ADR is $17.17B. A total of 0.57 million shares were traded on the day, compared to an average of 380.55K shares.
In the most recent transaction, Wang Xiaodong sold 41,760 shares of BGNE for 186.90 per share on Dec 10 ’24. After the transaction, the Chair, Scientific Advisory Brd now owns 0 company shares. In a previous transaction on Dec 09 ’24, BAKER BROS. ADVISORS LP sold 1,037,017 shares at 187.27 per share. BGNE shares that Director owns now total 791,493.
Among the insiders who bought shares, XIAODONG WANG acquired of 41,760 shares on Dec 10 ’24 at a per-share price of $207.62. In another insider transaction, 667, L.P. bought 86,110 shares at $187.27 per share on Dec 09 ’24.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, BGNE has a high of $248.16 and a low of $126.97.
As of this writing, BGNE has an earnings estimate of -$0.82 per share for the current quarter. EPS was calculated based on a consensus of 9.0 estimates, with a high estimate of $0.02 per share and a lower estimate of -$1.39.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. BGNE’s latest balance sheet shows that the firm has $6.62B in Cash & Short Term Investments as of fiscal 2021. There were $694.64M in debt and $1.60B in liabilities at the time. Its Book Value Per Share was $32.23, while its Total Shareholder’s Equity was $6.13B.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BGNE is Buy with a score of 4.67.
